To Evaluate the Efficacy and Tolerability of the Use of Vitatonus Dexa Compared to Dexamethasone in Patients With Neuralgia of Various Origins

• The causality of adverse events concerning the use of medication will be given after applying the Naranjo Algorythm [ Time Frame: Ten days ] [ Designated as safety issue: Yes ]
• Observation of adverse events related to medication [ Time Frame: Ten days ] [ Designated as safety issue: Yes ]

To evaluate the efficacy and tolerability of Vitatonus Dexa compared with dexamethasone in the signs and symptoms of neuralgia of various origins.

Clinical study, randomized prospective and random in nature, with a patients diagnosed with neuralgia of diverse origin.

Patients will be include in sufficient quantity to achieve the minimum of 104 evaluable patients.

• Experimental: Dexamethasone and complex vitamins

  Group A: Vitatonus dexa injectable:

  1 ampoule intramuscularly every 3 days for 10 days.

  Group B: Vitatonus DEXA tablet:

  1 tablet orally every 8 hours for 10 days.

  Intervention: Drug: Dexamethasone
• Active Comparator: Dexamethasone

  Group C: Dexamethasone Injectable:

  1 ampoule intramuscularly every 3 days for 10 days.

  Group D: Dexamethasone tablet:

  1 tablet orally every 8 hours for 10 days.

  Intervention: Drug: Dexamethasone

Inclusion Criteria:

1. Patients who consent to participate in the study by signing the ICF;
2. Patients of any ethnic group of both sexs aged over 18 years;
3. Patients with clinical diagnosis of neuralgia of various origins.
4. Patients who present scores on the Visual Analogue Scale (VAS) greater than or equal to 4 for PAIN.

Exclusion Criteria:

1. Patients with known hypersensitivity to lidocaine and thiamine or any component of the formula;
2. Pregnant women and nursing mothers;
3. Hypertensive or cardiac patients;
4. Patients with history of ulcers in the stomach or duodenum, diabetes mellitus or severe infections;
5. Patients who use levodopa, salicylates, colchicine, aminoglycosides, chloramphenicol, anticonvusivantes or potassium supplement.
6. Patient with a history of alcohol or use illicit drugs;